Topas Therapeutics Initiates Phase 2a Clinical Trial for TPM502 in Celiac Disease; Appoints Chief Business Officer and Chief Operating Officer

Building on positive clinical data from Topas' Phase 1 study of TPM203 in pemphigus vulgaris patients, the Phase 2a study in celiac disease patients initiates clinical development for TPM502 and

Related Keywords

Cristina De ,Galicia ,Spain ,Germany ,Barcelona ,Comunidad Autonoma De Cataluna ,Hamburg ,Christian Schr ,Gewinn Nur ,Erichf Greiner ,Priscillia Perrin ,Merck Group ,Johnson ,Novartis ,Boehringer Ingelheim Venture Fund ,Bristol Myers Squibb ,University Of Barcelona ,Trophic Communications ,Topa Phase ,Topas Particle Conjugates ,Cristina De Min ,Chief Medical Officer ,Chief Business Officer ,Chief Operating Officer ,Chief Medical ,Executive Chairman ,Topas Therapeutics ,Global Healthcare Operations ,Senior Director ,Pharma Business ,Particle Conjugates ,Epidarex Capital ,Vesalius Biocapital ,Business Officer ,Stopas ,Herapeutics ,Nitiates ,Hase ,Linical ,Trial ,Pm502 ,Celiac ,Disease ,Ppoints ,Chief ,Business ,Officer ,Operating ,